Literature DB >> 19009681

The risk for retinal detachment associated with hemorrhages pre- and postlaser treatment in retinopathy of prematurity.

Moon Jung Kim1, Seong-Joon Kim, Young Suk Yu.   

Abstract

PURPOSE: To determine the risk factors including retinal or vitreous hemorrhage for retinal detachment after laser photocoagulation in threshold or aggressive posterior retinopathy of prematurity.
METHODS: The medical records of 184 eyes of 94 consecutive infants who underwent diode laser photocoagulation for threshold or aggressive posterior retinopathy of prematurity between 1996 and 2006 were retrospectively reviewed. Eight clinical variables were included in the logistic regression analysis to assess the relationship between each variable and retinal detachment of 4A or greater.
RESULTS: The mean follow-up after laser photocoagulation was 25.06 +/- 23.59 months (range: 6-85 months). Sixteen (8.7%) eyes developed a retinal detachment. Pre and posttreatment retinal or vitreous hemorrhage was present in 30 (16.3%) eyes. Among 154 eyes without hemorrhage, 6 (3.9%) developed a retinal detachment, whereas 10 of 30 (33.3%) eyes with a hemorrhage developed a retinal detachment (P < 0.001). The logistic regression analysis showed that a pretreatment hemorrhage, vitreous organization, a persistent active element of plus disease after 21 days, and posttreatment hemorrhage were statistically associated with the development of a retinal detachment.
CONCLUSION: Pre and posttreatment hemorrhage was significantly associated with the progression to retinal detachment along with vitreous organization, a persistent plus disease activity 21 days after treatment.

Entities:  

Mesh:

Year:  2008        PMID: 19009681     DOI: 10.1097/iae.0b013e31817f2f15

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  9 in total

1.  Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series.

Authors:  Ramak Roohipoor; Hamed Ghasemi; Fariba Ghassemi; Reza Karkhaneh; Mohammad Riazi-Esfahani; Mehdi Nili-Ahmadabadi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-15       Impact factor: 3.117

2.  Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.

Authors:  Hossein Nazari; Mehdi Modarres; Mohammad Mehdi Parvaresh; Khalil Ghasemi Falavarjani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-27       Impact factor: 3.117

3.  Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP.

Authors:  Parveen Sen; Aditi Ashok Kumar Agarwal; Pramod Bhende; Suganeswari Ganesan
Journal:  Int Ophthalmol       Date:  2021-08-20       Impact factor: 2.031

4.  An inhibitor of endothelial ETS transcription factors promotes physiologic and therapeutic vessel regression.

Authors:  Christopher M Schafer; Jami M Gurley; Katarzyna Kurylowicz; Prisca K Lin; Wen Chen; Michael H Elliott; George E Davis; Faizah Bhatti; Courtney T Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-05       Impact factor: 11.205

Review 5.  80 Years of vision: preventing blindness from retinopathy of prematurity.

Authors:  Edward H Wood; Emmanuel Y Chang; Kinley Beck; Brandon R Hadfield; Amy R Quinn; Clio Armitage Harper
Journal:  J Perinatol       Date:  2021-03-05       Impact factor: 3.225

6.  Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage.

Authors:  Yu Xu; Xiaoli Kang; Qi Zhang; Qiujing Huang; Jiao Lv; Peiquan Zhao
Journal:  J Ophthalmol       Date:  2016-12-14       Impact factor: 1.909

7.  Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study.

Authors:  Qinrui Hu; Yujing Bai; Xiaoli Chen; Lvzhen Huang; Yi Chen; Xiaoxin Li
Journal:  J Ophthalmol       Date:  2017-04-09       Impact factor: 1.909

8.  Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.

Authors:  Qizhe Tong; Hong Yin; Mingwei Zhao; Xiaoxin Li; Wenzhen Yu
Journal:  BMC Ophthalmol       Date:  2018-06-26       Impact factor: 2.209

9.  Comment on: Variation in the vitreoretinal configuration of Stage 4 retinopathy of prematurity in photocoagulated and treatment-naive eyes undergoing vitrectomy.

Authors:  Gaurav Sanghi; Rajeev Gupta
Journal:  Indian J Ophthalmol       Date:  2018-03       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.